Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02599207 · ClinicalTrials.gov registry record · Phase 1
Assessment of the Safety of Allogeneic Umbilical Cord Blood Infusions in Children With Cerebral Palsy
A Phase 1 study, sponsored by Joanne Kurtzberg, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02599207 is a Phase 1 study that has completed, run by Joanne Kurtzberg, MD. The registered enrollment target is 15 participants.
The verdict
NCT02599207, a Phase 1 study, has completed, sponsored by Joanne Kurtzberg, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study is a single site, phase I, prospective study of the safety of intravenous sibling cord blood infusion in 15 children ages 1-6 years with Cerebral Palsy (CP). All subjects will be treated with sibling cord blood cells. The first six will receive cord blood cells from an HLA-matched sibling. The following nine subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. The duration of study participation will be six months from the time of the cord blood infusion.
Interventions
- BIOLOGICAL sibling umbilical cord blood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02599207
The ClinicalTrials.gov registry entry for NCT02599207 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joanne Kurtzberg, MD, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sibling umbilical cord blood is the first listed.
NCT02599207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02599207 about?
NCT02599207 is a clinical study titled "Assessment of the Safety of Allogeneic Umbilical Cord Blood Infusions in Children With Cerebral Palsy". This study is a single site, phase I, prospective study of the safety of intravenous sibling cord blood infusion in 15 children ages 1-6 years with Cerebral Palsy (CP). All subjects will be treated with sibling cord blood cells. The first six will receive cord blood cells from an HLA-matched sibling...
What is the current status of trial NCT02599207?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-11. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02599207?
The interventions under investigation include: sibling umbilical cord blood (BIOLOGICAL).
Who is sponsoring clinical trial NCT02599207?
This trial is sponsored by Joanne Kurtzberg, MD, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.